Novartis Pharmaceuticals Corporation v. Bailey

CourtDistrict Court, W.D. Missouri
DecidedNovember 14, 2024
Docket2:24-cv-04131
StatusUnknown

This text of Novartis Pharmaceuticals Corporation v. Bailey (Novartis Pharmaceuticals Corporation v. Bailey) is published on Counsel Stack Legal Research, covering District Court, W.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Novartis Pharmaceuticals Corporation v. Bailey, (W.D. Mo. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI CENTRAL DIVISION

NOVARTIS PHARMACEUTICALS ) CORPORATION, ) ) Plaintiff, ) ) vs. ) Case No. 2:24-cv-04131-MDH ) ANDREW BAILEY, in his official capacity as ) ATTORNEY GENERAL OF THE STATE OF ) MISSOURI; JAMES L. GRAY, in his official ) capacity as President of the Missouri Board of ) Pharmacy; CHRISTAN S. TADRUS, in his ) official capacity as Vice-President of the ) Missouri Board of Pharmacy; and DOUGLAS ) R. LANG, ANITA K. PARRAN, COLBY ) GROVE, TAMMY THOMPSON, and DARREN ) HARRIS, in their official capacities as members ) of the Missouri Board of Pharmacy, ) ) Defendants. )

ORDER Before the Court is the Missouri Hospital Association (“MHA”) and Missouri Primary Care Association’s (“MPCA”) (collectively the “Proposed Intervenors”) Motion to Intervene. (Doc. 25). Plaintiff has filed suggestions in opposition of the intervention (Doc. 44) and Defendants have no position regarding MHA and MPCA intervening. BACKGROUND This case arises out of Senate Bill (“SB”) 751 which created protections to the delivery of 340B drugs to contract pharmacies on behalf of “covered entities”. Section 340B incentivizes pharmaceutical manufactures to provide qualified health care providers, referred to as “covered entities,” with pricing discounts on certain drugs prescribed to individuals and families whose income falls below the federal poverty level. Covered entities have contracted with outside pharmacies or “contract pharmacies,” for the distribution and dispensation of 340B drugs. SB 751 protects hospitals, federal qualified health centers (“FQHC”), and their patients from drug manufacturers’ restrictions on the number of contract pharmacies a hospital or FQHC can use and

still receive discount pricing under 340B plan. Plaintiff is a corporation organized in Delaware with its principal place of business in New Jersey. Defendants are all residents of Missouri that are responsible for administering and enforcing the provisions of SB 751. MHA and MPCA are looking to intervene in this matter on behalf of their respective members. MHA is a Missouri, not-for-profit member organization whose mission is to shape an

environment that enables member hospitals and healthcare systems to meet their evolving missions so that they may improve the health of their patients and community. MHA has 139 hospital members approximately half of which are “covered entitles” in the 340B program. MPCA is a Missouri, not-for-profit member organization whose mission is to be Missouri’s leader in shaping policies and programs that improve access to high-quality, community-based, and affordable primary health services. MPCA’s members are Missouri community health centers that serve low income and medically under-served communities. All of MPCA’s members are “covered entitles” in the 340B program.

STANDARD “An Article III case or controversy is one where all parties have standing, and a would-be

intervenor, because he seeks to participate as a party, must have standing as well.” Liddell v. Special Admin. Bd. Of Transitional Sch. Dist. Of City of St. Louis, 894 F.3d 959, 964 (8th Cir. 2018) (quoting Mausolf v. Babbitt, 85 F.3d 1295, 1300 (8th Cir. 1996). A prospective intervenor, then, must satisfy requirements of Article III standing. Liddell at 964. The Intervenor must have “(1) suffered an injury in fact, (2) that is fairly traceable to the challenged conduct of the defendant, and (3) that is likely to be redressed by a favorable judicial decision. Spokeo, Inc. v. Robins, --- U.S.----, 136 S.Ct. 1540, 1547, 194 L.Ed. 2d 635 (2016). To establish an injury in fact, the

intervenor must show he or she suffered “‘an invasion of a legally protected interest’ that is ‘concrete and particularized’ and ‘actual or imminent, not conjectural or hypothetical.’” Id. at 1548 (quoting Lujan v. Defs. Of Wildlife, 504 U.S. 555, 560, 112 S.Ct. 2130, 119 L.Ed. 2d 351 (1992). The court must permit anyone to intervene as a matter of right if: (1) the motion is timely; (2) the intervenor “claims an interest relating to the property or transaction that is subject of the

action”; (3) disposition of the action “may as a practical matter impair or impede the movant’s ability to protect its interest”; and (4) the existing parties do not “adequately represent” the interest. Fed. R. Civ. P. 24(a)(2). ANALYSIS

I. The Proposed Intervenors Have Standing MHA and MPCA are intervening on behalf of their members. When the proposed

intervenors are an organization, the standing requirement can be satisfied in two ways; either the organization can claim that it suffered an injury in its own right or it can assert solely as the representative of its members. Students for Fair Admissions, Inc. v. Pres. and Fellows of Harvard College, 600 U.S. 181, 199 (2023). To invoke associational standing an organization must demonstrate that “(a) its members would otherwise have standing to sue in their own right; (b) the interests it seeks to protect are germane to the organization’s purpose; and (c) neither the claim asserted nor the relief requested requires the participation of individual members in the lawsuit. Id. (quoting Hunt v. Washington State Apple Advertising Comm’n, 432 U.S. 333, 343, 97 S.Ct. 2434, 53 L.Ed.2d 383 (1977).

Both Proposed Intervenors have standing. MHA in its related motions to intervene specifically point to an individual member who uses multiple contract pharmacies and would be harmed by restrictions set by drug manufactures relating to contract pharmacies.1 Likewise, MPCA’s demonstrates in related motions that two of their members use multiple contract pharmacies and therefore would be harmed if contract pharmacy restrictions would be allowed. They have demonstrated an injury-in-fact that is a legally protected interest, concrete and particularized and would be an actual or imminent injury if SB 751 were to be found

unenforceable. The Proposed Intervenors argue that if Plaintiff is successful, its members could trace their injuries to the court order barring enforcement of SB 751. The harms alleged by members of the Proposed Intervenors would be redressable by this Court based on a favorable decision to allow SB 751 to be enforced. The Court finds this sufficient to establish the Proposed Intervenors members have standing to sue in their own right. Additionally, both MHA and MPCA’s mission statements are germane to the organizations purpose and neither the claim asserted, nor the relief requested requires the participation of individual members in the lawsuit. Therefore, the Proposed Intervenors have associational standing in this case.

II. The Proposed Intervenors Are Permitted to Intervene as a Matter of Right a. The Proposed Intervenors Motion is Timely

1The Proposed Intervenors’ motion in this case did not identify a specific member and their individual injury that would give them standing to sue in its members place. See Religious Sisters of Mercy v. Becerra, 55 F.4th 583, 602 (8th Cir. 2022) (holding that A court cannot accept the organizations’ self-descriptions of their membership because the court has an independent obligation to assure that standing exists).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Novartis Pharmaceuticals Corporation v. Bailey, Counsel Stack Legal Research, https://law.counselstack.com/opinion/novartis-pharmaceuticals-corporation-v-bailey-mowd-2024.